Focus: Fosun Pharma is a publicly listed diagnostics and specialty pharma company headquartered in Sydney, operating across oncology, neurology, cardiovascular, infectious diseases, and respiratory therapeutics since 1994. The company balances marketed small-molecule drugs with an active pipeline spanning Phase 1–3 development.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Fosun Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Fosun Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fosun Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product generating 24% of company revenue with 11-year LOE runway, demonstrating durable commercial strength in ophthalmology.
Post-LOE ANDA generating significant Medicare spending but facing generic competition and declining lifecycle pressure.
Established ANDA in mature osteoporosis market with stable but declining revenue from generic competition.
Peak-lifecycle NDA with 10-year LOE runway and oncology positioning, supporting mid-term revenue stability.
Post-LOE ANDA in niche neurology indication facing generic erosion with limited growth potential.
Alternative formulation of same molecule generating $20M in Part D spending but subject to similar generic and lifecycle pressures.
NDA formulation of abiraterone with 8-year LOE runway, complementing generic abiraterone portfolio in prostate cancer.
Niche dental NDA with approaching LOE and minimal revenue contribution, representing end-of-lifecycle product.
183 discontinued, 106 duplicate formulations not shown
+3 more products with revenue data
Fosun cleared to conduct clinical trials with FXR-0906 - BioWorld News
Fosun cleared to conduct clinical trials with FXR-0906 BioWorld News
Fosun Pharma (600196.SH): A drug developed by its majority-owned subsidiary has received approval to commence clinical trials. - 富途牛牛
Fosun Pharma (600196.SH): A drug developed by its majority-owned subsidiary has received approval to commence clinical trials. 富途牛牛
AriBio receives remaining $50 mil. payment from Fosun for oral Alzheimer’s drug - koreabiomed.com
AriBio receives remaining $50 mil. payment from Fosun for oral Alzheimer’s drug koreabiomed.com
AriBio Receives Full Upfront Payment From Fosun Pharma for Alzheimer's Drug Deal - Seoul Economic Daily
AriBio Receives Full Upfront Payment From Fosun Pharma for Alzheimer's Drug Deal Seoul Economic Daily
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials - Fierce Pharma
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials Fierce Pharma
Fosun Pharma (600196.SH): A drug developed by its majority-owned subsidiary has received approval to commence clinical trials. - 富途牛牛
Fosun Pharma (600196.SH): A drug developed by its majority-owned subsidiary has received approval to commence clinical trials. 富途牛牛
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+77 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo